POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS (project)

Guidelines of Methodological Standards for Pharmacoeconomic Evaluations in Taiwan

Impact Of Pharmacoeconomic Guidelines on the Reimbursement Process of Medicines In Serbia In 2014.

METHODS We investigated the budget impact analysis made by pharmaceutical companies, in the period September 2013 to June 2014. Quality was assessed using the criteria for pharmacoeconomic evaluations from the in the most recent ISPOR guidelines and the Serbian pharmacoeconomic guidelines. The impact of the introduction of the new rulebook was assessed by comparing the period following its intr...

Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries.

BACKGROUND Financial analysis (budget impact analysis, BIA) is increasingly required by decision-makers to ascertain the macroeconomic consequences of new product reimbursement in addition to proof of cost-effectiveness. Poland is in the process of drafting country-specific guidelines for BIA, positioned as complementary to economic evaluation in decision-making OBJECTIVES The aim of this art...

“Budget Impact Analyses”: a practical policy making tool for drug reimbursement decisions

Increasing accessibility and affordability of healthcare services has been considered as an important policy objective since the beginning of 1980s in Iran. However, current 60- 70% health care out-of-pocket payments create a barrier to an equal access to quality health services, especially in terms of new medicines which affects equity issues and "health" in Iran. Currently, health insurance o...

“Budget Impact Analyses”: a practical policy making tool for drug reimbursement decisions

Increasing accessibility and affordability of healthcare services has been considered as an important policy objective since the beginning of 1980s in Iran. However, current 60- 70% health care out-of-pocket payments create a barrier to an equal access to quality health services, especially in terms of new medicines which affects equity issues and "health" in Iran. Currently, health insurance o...